Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,067 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Carcinogenicity of cobalt, antimony compounds, and weapons-grade tungsten alloy.
Karagas MR, Wang A, Dorman DC, Hall AL, Pi J, Sergi CM, Symanski E, Ward EM, Arrandale VH, Azuma K, Brambila E, Calaf GM, Fritz JM, Fukushima S, Gaitens JM, Grimsrud TK, Guo L, Lynge E, Marinho-Reis AP, McDiarmid MA, Middleton DRS, Ong TP, Polya DA, Quintanilla-Vega B, Roberts GK, Santonen T, Sauni R, Silva MJ, Wild P, Zhang CW, Zhang Q, Grosse Y, Benbrahim-Tallaa L, de Conti A, DeBono NL, El Ghissassi F, Madia F, Reisfeld B, Stayner LT, Suonio E, Viegas S, Wedekind R, Ahmadi S, Mattock H, Gwinn WM, Schubauer-Berigan MK. Karagas MR, et al. Among authors: azuma k. Lancet Oncol. 2022 May;23(5):577-578. doi: 10.1016/S1470-2045(22)00219-4. Epub 2022 Apr 7. Lancet Oncol. 2022. PMID: 35397803 No abstract available.
Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study.
Passaro A, Wang J, Wang Y, Lee SH, Melosky B, Shih JY, Wang J, Azuma K, Juan-Vidal O, Cobo M, Felip E, Girard N, Cortot AB, Califano R, Cappuzzo F, Owen S, Popat S, Tan JL, Salinas J, Tomasini P, Gentzler RD, William WN Jr, Reckamp KL, Takahashi T, Ganguly S, Kowalski DM, Bearz A, MacKean M, Barala P, Bourla AB, Girvin A, Greger J, Millington D, Withelder M, Xie J, Sun T, Shah S, Diorio B, Knoblauch RE, Bauml JM, Campelo RG, Cho BC; MARIPOSA-2 Investigators. Passaro A, et al. Among authors: azuma k. Ann Oncol. 2024 Jan;35(1):77-90. doi: 10.1016/j.annonc.2023.10.117. Epub 2023 Oct 23. Ann Oncol. 2024. PMID: 37879444 Free article. Clinical Trial.
A case of salvage surgery following chemoradiotherapy and durvalumab for initially unresectable superior sulcus tumor with N3 involvement.
Manabe T, Kanayama M, Matsumiya H, Yoshimatsu K, Mori M, Nishizawa N, Taira A, Takenaka M, Kuroda K, Azuma K, Tanaka F. Manabe T, et al. Among authors: azuma k. Gen Thorac Cardiovasc Surg Cases. 2024 Oct 1;3(1):44. doi: 10.1186/s44215-024-00169-z. Gen Thorac Cardiovasc Surg Cases. 2024. PMID: 39516998 Free PMC article.
Averaged Oxygen Desaturation Improves the Prognostic Value of the Six-Minute Walk Test in Elderly Patients with Heart Failure.
Sunayama I, Min KD, Orihara Y, Ono J, Matsumoto Y, Daimon A, Soyama Y, Manabe E, Oboshi M, Azuma K, Sugahara M, Eguchi A, Naito Y, Suna S, Asakura M, Ishihara M. Sunayama I, et al. Among authors: azuma k. Am J Physiol Heart Circ Physiol. 2024 Nov 8. doi: 10.1152/ajpheart.00578.2024. Online ahead of print. Am J Physiol Heart Circ Physiol. 2024. PMID: 39514007
Efficacy of immune checkpoint inhibitors plus platinum-based chemotherapy as 1st line treatment for patients with non-small cell lung cancer harboring HER2 mutations: Results from LC-SCRUM-Asia.
Kato Y, Udagawa H, Matsumoto S, Izumi H, Ohe Y, Kato T, Nishino K, Miyamoto S, Kawana S, Chikamori K, Shingyoji M, Sato Y, Takada Y, Toyozawa R, Azuma K, Tanaka Y, Sakai T, Shibata Y, Sugiyama E, Nosaki K, Zenke Y, Umemura S, Yoh K, Seike M, Goto K. Kato Y, et al. Among authors: azuma k. Lung Cancer. 2024 Nov;197:107992. doi: 10.1016/j.lungcan.2024.107992. Epub 2024 Oct 13. Lung Cancer. 2024. PMID: 39423763
Final Analysis Data and Exploratory Biomarker Analysis of a Randomized Phase 2 Study of Osimertinib Plus Bevacizumab Versus Osimertinib Monotherapy for Untreated Patients With Nonsquamous NSCLC Harboring EGFR Mutations: The WJOG9717L Study.
Kenmotsu H, Sakai K, Mori K, Kato T, Sugawara S, Kirita K, Yoneshima Y, Azuma K, Nishino K, Teraoka S, Koyama R, Masuda K, Hayashi H, Toyozawa R, Miura S, Sato Y, Nakagawa K, Yamamoto N, Nishio K, Takahashi T. Kenmotsu H, et al. Among authors: azuma k. JTO Clin Res Rep. 2024 Aug 23;5(11):100716. doi: 10.1016/j.jtocrr.2024.100716. eCollection 2024 Nov. JTO Clin Res Rep. 2024. PMID: 39399795 Free PMC article.
Whole-exome sequencing reveals the genetic causes and modifiers of moyamoya syndrome.
Nakamura A, Nomura S, Hara S, Thamamongood T, Maehara T, Nariai T, Khairullah S, Tan KS, Azuma K, Chida-Nagai A, Furutani Y, Hori T, Yamaguchi K, Kawamata T, Roder C, Akagawa H. Nakamura A, et al. Among authors: azuma k. Sci Rep. 2024 Oct 4;14(1):22720. doi: 10.1038/s41598-024-72043-5. Sci Rep. 2024. PMID: 39367156 Free PMC article.
1,067 results